EZH2 and acute myeloid leukemia: On the basis of pre-clinical studies demonstrating the functional importance of PRC2 in MLL-rearranged AML, the dual EZH1–EZH2 inhibitor DS3201b has entered phase 1 as monotherapy in patients with refractory acute leukemia (NCT03110354) (Table 1).